Bladder cancer
Conditions
Interventions
Gold Standard:Pathology results of TURBT or cystoscopy
Index test:mRNA and lncRNA in urinary exosomes
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Case Group: 1. Age >= 18 years, no gender restrictions; 2. Patients with clinical indications not excluding bladder malignancy, undergoing initial or repeat cystoscopic biopsy or transurethral resection of bladder tumor (TURBT) (initial pathology being non-muscle-invasive bladder cancer), with positive postoperative pathology; 3. Able to sign an informed consent form, willing to comply with protocol requirements, demonstrate good compliance, and cooperate with center follow-up. Control Group: 1. Age >= 18 years, no gender restrictions; 2. Healthy individuals or patients clinically diagnosed with benign urological conditions, including: urinary tract stones, renal cysts, ureteral strictures, urethral strictures, hypospadias, benign prostatic hyperplasia, urinary tract infections, chronic prostatitis, adenomatous cystitis, and other benign urological diseases; Patients undergoing TURBT for the first time or as a repeat procedure (with initial pathology showing non-muscle-invasive bladder cancer) and receiving negative postoperative pathology or negative combined cystoscopy and urinary cytology results; 3. Able to sign an informed consent form, willing to comply with protocol requirements, demonstrate good compliance, and cooperate with follow-up visits at the participating center.
Exclusion criteria
Exclusion criteria: 1. Individuals with incomplete samples or clinical data; 2. Patients with autoimmune diseases, traumatic conditions, or concurrent systemic tumors; 3. Individuals undergoing systemic chemotherapy, immunotherapy, or radiotherapy prior to urine collection; 4. Patients with urinary tract infections who have received antibiotic treatment within the past five days; 5. Individuals with concurrent urogenital tumors (prostate cancer or renal carcinoma); 6. History of other malignancies within the past five years or prior anticancer therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRNA and lncRNA Expression in Urinary Exosomes;Area Under Curve;Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactHailong Hu, Haifang Yin
The Second Hospital of Tianjin Medical University
Outcome results
None listed